Skip to content
Accessibility help
Search NICE…
Skip to content
Menu
Sign in
Guidance
Standards and indicators
Life sciences
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Clinical Knowledge Summaries (CKS)
About
Home
NICE guidance
Awaiting development
Awaiting development: Guidance and quality standards
Skip to filters
Skip to results
Published
In consultation
In development
Awaiting development
Topic selection
Filter
Skip to results
Keyword or reference number
Keyword or reference number
Apply filter
Area of interest
Area of interest
COVID-19 (11)
Type
Type
Guidance (304)
Quality standard (31)
Guidance programme
Guidance programme
Diagnostics guidance (1)
Health technology evaluations (6)
Highly specialised technologies guidance (1)
Interventional procedures guidance (6)
Medical technologies guidance (5)
Technology appraisal guidance (285)
Apply filters
Showing 131 to 140 of 335
Guidance and quality standards awaiting development
Title
Type
Idecabtagene vicleucel for treating relapsed or refractory multiple myeloma after 2 to 4 therapies ID 6491
Technology appraisal guidance
Imetelstat for treating intermediate-2 or high-risk relapsed or refractory myelofibrosis after a JAK inhibitor TS ID 8376
Technology appraisal guidance
In-situ Normothermic Regional Perfusion system for DCD donors
Interventional procedures guidance
Inavolisib with palbociclib and fulvestrant for treating HR+/HER2-, PIK3CA mutated locally advanced or metastatic breast cancer TS ID 11990
Technology appraisal guidance
Inebilizumab for treating AQP4-IgG seropositive neuromyelitis optica spectrum disorders ID6430
Technology appraisal guidance
Infant, children and young people's experience of health care
Quality standard
Inolimomab (Leukotac) for acute Graft versus host disease (aGvHD) after Allo-HSCT [ID3923]
Technology appraisal guidance
Insertion of a Catheter based intravascular microaxial blood pump for acute heart failure
Interventional procedures guidance
Invimestrocel for treating acute ischaemic stroke within 18 to 36 hours of onset TS ID 10190
Technology appraisal guidance
Irbesartan–propagermanium for treating focal segmental glomerulosclerosis in people 12 years and over having an angiotensin II receptor blocker ID 6469
Technology appraisal guidance
Previous page
1
…
12
13
Current page
14
15
16
…
34
Page
14
of
34
Next page
Results per page
10
25
50
All
Back to top